TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04807244

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Selective Caries Removal with Biodentine™
Description: 1. Rubber dam placement~2. Cleaning of the tooth and rubber dam with ethanol 98%~3. Caries removal: Removal of protruding parts of enamel/dentin with high-speed round bur with continuous water cooling, caries removal with a low-speed round bur; peripheral caries is removed until only hard dentin is left, while the pulp wall is excavated until reaching leathery dentin~4. Disinfection of the leathery dentin 5 ml 1% NaOCl (speed: 1 ml per min)~5. Indirect pulp capping (layer of 1-2 mm) of the carious lesion with Biodentine™ (15 min setting time after mixing)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Partial Pulpotomy with Biodentine™
Description: 1. Rubber dam placement~2. Cleaning of the tooth and rubber dam with ethanol 98%~3. Caries removal: Removal of protruding parts of enamel/dentin with high-speed round bur with continuous water cooling, caries removal with a low-speed round bur; before accessing the pulp chamber, the central caries will be left, peripheral caries will be excavated completely~4. Disinfection of the leathery dentin 5 ml NaOCl 1% (speed: 1 ml per min)~5. Accessing the pulp chamber with a high-speed round bur and removal of 2-3 mm pulp tissue; irrigation with 2 ml NaOCl 1%~6. Hemostasis will be achieved with a sterile foam pellet soaked with NaOCl 1% with gentle pressure to the pulp for 3 min~7. If hemostasis could not be achieved within 3 min, step 6 will be repeated once. In case of no hemostasis, transfer of the case to Intervention: full pulpotomy with Biodentine~8. Confirmed hemostasis: pulp capping with Biodentine™ (layer min. 2-3 mm, 15 min setting time after mixing)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Full Pulpotomy with Biodentine™
Description: 1. Rubber dam placement~2. Cleaning of the tooth and rubber dam with ethanol 98%~3. Caries removal: Removal of protruding parts of enamel/dentin with high-speed round bur with continuous water cooling, caries removal with a low-speed round bur; before accessing the pulp chamber, the central caries will be left, peripheral caries will be excavated completely~4. Disinfection of the leathery dentin 5 ml NaOCl 1% (speed: 1 ml per min)~5. Accessing the pulp chamber with a high-speed round bur and removal of the entire pulp chamber roof; full pulpotomy to stump level with a high-speed round bur under continuous irrigation with 5 ml NaOCl 1%~6. Hemostasis will be achieved with a sterile foam pellet soaked with NaOCl 1% with gentle pressure to the pulp for 3 min~7. If hemostasis could not be achieved within 3 min, step 6 will be repeated once. In case of no hemostasis, exclusion.~8. Confirmed hemostasis: pulp capping with Biodentine™ (layer min. 2-3 mm, 15 min setting time after mixing)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Direct composite filling after selective caries removal/full pulpotomy/partial pulpotomy
Description: 1. Dentin cleaning with a low-speed round bur~2. Use of Scotchbond Universal™ and Filtek Supreme XTE™ according to manufacturer's recommendation
Study: NCT05844943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReHeal glove with Negative Pressure Wound Therapy (NPWT)
Description: ReHeal glove hand dressing with Negative Pressure Wound Therapy (NPWT).
Study: NCT06316934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lavandula angustifolia, Aura Cacia
Description: Lavender essential oil will be placed on paper towel which patient will deeply inhale prior to the start of the procedure.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Distilled water will be placed on paper towel which patient will deeply inhale prior to the start of the procedure.
Study: NCT04807244

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Direct composite filling after selective caries removal/full pulpotomy/partial pulpotomy
Description: 1. Dentin cleaning with a low-speed round bur~2. Use of Scotchbond Universal™ and Filtek Supreme XTE™ according to manufacturer's recommendation
Study: NCT05841277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3819469
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3819469
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3819469
Description: Administered SC.
Study: NCT05327244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-world vibration feedback gait retraining
Description: Participants will walk with a vibration feedback tool attached to their shoelaces. A small force sensing resistor is taped to the foot bed of the shoe under the lateral foot and a vibration motor is placed over the outside of the ankle with a strap. When a participant walks on the outside of their foot, they will exceed the pressure threshold and activate the feedback which signifies an incorrect foot placement. The feedback is intended to prompt a correct foot placement on the subsequent step. Participants will use the same feedback tool for 6 real world training sessions.
Study: NCT05789706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dayamed Arthur a novel intelligent medication adherence platform
Description: Novel smart phone adherence application configured with subject pharmacy data providing accurate reminders of when to take medications and providing auditable user feed back to clinical care teams for patient response directed provider intervention.
Study: NCT05536557

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral External Oblique İntercostal (EOI) Plane Block
Description: External Oblique İntercostal (EOI) Plane Block will be provided for postoperative pain for Laparoscopic Cholecystectomy with Bupivacaine. And patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard perioperative and postoperative multimodal analgesia
Description: Patients will receive standard multimodal analgesia comprising paracetamol, deksketoprofen, and tramadol for Laparoscopic Cholecystectomy.
Study: NCT05524857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib Oral Capsule 300 mg
Description: 300 mg by mouth, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m2
Description: 20 mg/m2 for injection, for intravenous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m2
Description: 20 mg/m2 for injection, for intravenous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib Oral Capsule 400 mg
Description: 400 mg by mouth, once daily
Study: NCT05733234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser ,Fotona, Light Walker AT, Ljubljana, Slovenia
Description: Laser is used adjunctively in the surgical treatment of peri-implantitis for decontamination of the implant surface

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Treatment
Description: Dental instrument is used in combination with Chlorhexidine to decontaminate the implant surface
Study: NCT05577000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Manufactured Anti-BCMA CAR-T cells
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Manufactured Anti-BCMA CAR-T cells
Description: Given IV
Study: NCT05194137

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a proprioception protocol associated with vaginal palpation and feedback
Description: A total of 13 previously established examples of voice commands can be used by the physiotherapists to help women understand how to perform a PFM contraction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a proprioception protocol associated with biofeedback
Description: The software has five different interfaces for visualize PFM contraction: sign itself and signal transformed into the movement of a balloon; an airplane; a fairy; or a bird. Positive reinforcements will be verbalized after each PFM contraction using one of 4 previously established examples of voice commands.
Study: NCT06328062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirogabalin
Description: Participants will receive 5 mg of mirogabalin, taken as half a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Participants will receive 50 mg of pregabalin, taken as a tablet, every day twice a day, after breakfast and dinner, for 6 weeks.
Study: NCT05486481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given orally (PO)
Study: NCT05524155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC
Description: hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg IV d1,Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: 80mg/day,PO,QD,d1～21,Q4W
Study: NCT06254404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose protamine
Description: Administration of 70% of the normal dose of protamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose protamine
Description: Administration of 70% of the normal dose of protamine
Study: NCT06180070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nuromol® tablets
Description: 1 tablet of 200mg Ibuprofen/ 500mg Paracetamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nuromol® tablets
Description: 1 tablet of 200mg Ibuprofen/ 500mg Paracetamol
Study: NCT05577000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Manufactured Anti-BCMA CAR-T cells
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Manufactured Anti-BCMA CAR-T cells
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study: NCT04562727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: perioperative chemotherapy or postoperative chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: perioperative chemotherapy or postoperative chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: perioperative chemotherapy or postoperative chemotherapy
Study: NCT05391412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate Human
Description: Patients in the intervention group will receive single administration of fibrinogen concentrate intravenously at a dose of 20-30 mg/kg (depending on body weight and clinical condition, according to SmPC). The medicinal product will be diluted in a 100 ml infusion bag and administered after induction of anaesthesia prior beginning of surgery. The infusion rate should not exceed approximately 5 ml per minute.
Study: NCT06009393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1918
Description: Three administration
Study: NCT06511284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein dose
Description: High dose of protein (2.0 g/kg) will prescribed for home enteral nutrition

Intervention type: OTHER
Group type: OTHER
Intervention: Usual protein dose
Description: Usual dose of protein (1.5 g/kg) will prescribed for home enteral nutrition
Study: NCT05486481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given Subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given Subcutaneously (SC)
Study: NCT04643574

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoTIL
Description: Adoptive transfer of ex vivo expanded Autologous Tumor-Infiltrating Lymphocytes enriched for tumor antigen specificity (NeoTIL)
Study: NCT05486481

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyclin D1 gene (CCDN1) /immunoglobulin heavy chain (IGH) fluorescence in situ hybridization (FISH) assay
Description: Lab test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyclin D1 gene (CCDN1) /immunoglobulin heavy chain (IGH) fluorescence in situ hybridization (FISH) assay
Description: Lab test
Study: NCT05102812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breakfast Group Intervention
Description: An actionable toolkit encompassing an assessment, a personalised care plan and a range of outcome measures.
Study: NCT05577000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT04643574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered as an intravenous (IV) infusion for five days.
Study: NCT05337735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb20717
Description: Given by vein (IV)
Study: NCT04995731

Intervention type: BEHAVIORAL
Intervention: Information about clinical risk factors for endometrial cancer and endometrial hyperplasia (EH)
Description: Bleeding type, age, race, parity, early menarche or late menopause, body mass index, body composition, hypertension, type II diabetes, anovulation, polycystic ovary syndrome and smoking history. Other epidemiologic risk factors including tamoxifen exposure, history of breast cancer, current hormone therapy use, anticoagulant use, oral contraception use, family history of endometrial, breast or colon cancer.

Intervention type: PROCEDURE
Intervention: transvaginal ultrasound examination
Description: All patients will undergo a standard transvaginal ultrasound examination followed by power Doppler endometrial vascularity assessment. After ultrasound examination, all patients will undergo endometrial sampling either through hysteroscopy or dilatation and curettage operation (D, C) or will have histopathological evaluation of biopsy specimens obtained by hysterectomy. Histopathological evaluation will serve as a gold standard for the ﬁnal diagnosis.
Study: NCT05577000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT05895331

Intervention type: DIAGNOSTIC_TEST
Intervention: Thiol/Disulphide Homeostasis
Description: An automated analysis quantitatively measuring serum native and total thiol, and disulfides has been recently described as a method to determine dynamic Thiol/Disulfide Homeostasis (TDH).

Intervention type: DIAGNOSTIC_TEST
Intervention: Thiol/Disulphide Homeostasis
Description: An automated analysis quantitatively measuring serum native and total thiol, and disulfides has been recently described as a method to determine dynamic Thiol/Disulfide Homeostasis (TDH).
Study: NCT04985201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan intravenous infusion was administered at a dose of 60 mg/m\^2 on Day 1,8 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan intravenous infusion was administered at a dose of 60 mg/m\^2 on Day 1,8 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 40 mg daily oral tablet taken.
Study: NCT05421624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital music therapeutic
Description: The digital music therapeutic is comprised of foot sensors, a smart phone with pre-installed proprietary software application, and headphones. The device obtains real-time walking data through movement sensors that communicate wirelessly with the smartphone application software. Music cues are tailored to the person's walking pattern, and are transmitted wirelessly to the headphones. Music cues are time-shifted to the user's baseline cadence and adjusted in real-time based on the user's walking performance metrics.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active-Control
Description: The Active-Control intervention will implement a similarly structured community-based walking program as Amped-PD, with the only exception the digital music therapeutic.
Study: NCT05798169

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Resistance training
Description: Moderate resistance training by a innovative training robot 2 times a day during hospitalisation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Moderate resistance training by a innovative training robot 2 times a day during hospitalisation
Study: NCT04643574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of fourteen doses.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Low-dose irradiation (1Gy) will be administered using tomotherapy to tumor lesions once before NeoTIL infusion.
Study: NCT05136209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCCC procedure without A-vit
Description: In this randomized clinical trial, patients receive cataract surgery on both eyes on the same day. For each patient, one eye is randomly assigned to undergo PCCC+A-Vit procedure, while the fellow eye is undergoing PCCC procedure without A-Vit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCCC+A-Vit procedure
Description: PCCC+A-Vit procedure
Study: NCT06039904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Natural rubber knee support
Description: The knee support comprised two parts, the support body and the protective cushion. Which were categorized into four sizes, S, M, L and XL according to widths and lengths, as follows: size S, 8x17 cm; size M, 10x19 cm; size L, 12x24 cm; and size XL, 14x28 cm. The support body was made of stretchable natural cotton fabrics, which were comfortable, breathable, washable, less irritant and flexible. Similarly, the protective cushion was classified into four sizes: S, M, L and XL with diameters (based on the patellar diameters) of 5, 6, 7 and 8 cm, respectively. Cushions were made from either natural rubber and inserted at the front of the support body (to cover the patellar).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sponge knee support
Description: The knee support comprised two parts, the support body and the protective cushion. Which were categorized into four sizes, S, M, L and XL according to widths and lengths, as follows: size S, 8x17 cm; size M, 10x19 cm; size L, 12x24 cm; and size XL, 14x28 cm. The support body was made of stretchable natural cotton fabrics, which were comfortable, breathable, washable, less irritant and flexible. Similarly, the protective cushion was classified into four sizes: S, M, L and XL with diameters (based on the patellar diameters) of 5, 6, 7 and 8 cm, respectively. Cushions were made from either sponge and inserted at the front of the support body (to cover the patellar).
Study: NCT05230264

Intervention type: OTHER
Intervention: Elective AAA Repair
Description: Elective AAA Repair - Observation of Stress Response

Intervention type: OTHER
Intervention: Elective AAA Repair
Description: Elective AAA Repair - Observation of Stress Response
Study: NCT05335044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-331
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-331
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EX5619
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EX5619
Description: QD, PO
Study: NCT06174948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CUE1 non-invasive device
Description: This is a 9-week feasibility study which will involve wearing the CUE1 device on a daily basis at participants' homes while they continue their usual activities of daily living (ADL). The CUE1 is a non-invasive medical device which delivers low frequency metronomes like tactile cueing and high frequency focused vibrotactile stimulation. All participants will be using the same pre-programmed settings for the CUE1 device which are: vibration strength delivered at 80%, pulse length 800 milliseconds (ms), and rest length 800ms as set at baseline and will not change. The CUE1 device is attached to the skin via an adhesive patch which has been dermatologically tested and approved. Participants will be provided with the adhesive patches and shown how to use them and the CUE1 device by the research team.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CUE1+ device active vs sham CUE1+ device
Description: 30-40 participants with idiopathic Parkinson's disease only will be randomly allocated to one of two interventions groups: one group will use the active CUE1+ device while the other group will use the CUE1+ at silent settings (e.g., sham device). All participants will use their device in the same way which is starting the usage from the morning, within an hour once they took their medications for Parkinson's (if any) and continue using the device for 8 hours, once a day, every day for 12 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CUE1+ device active vs sham CUE1+ device
Description: 30-40 participants with idiopathic Parkinson's disease only will be randomly allocated to one of two interventions groups: one group will use the active CUE1+ device while the other group will use the CUE1+ at silent settings (e.g., sham device). All participants will use their device in the same way which is starting the usage from the morning, within an hour once they took their medications for Parkinson's (if any) and continue using the device for 8 hours, once a day, every day for 12 weeks
Study: NCT04638816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Volyme
Description: Hyaluronic Acid: Injectable gel for contouring effect (of cheek volumization).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Lyft Lidocaine
Description: Hyaluronic Acid: Injectable gel for projection effect (of cheek augmentation).